MASH dash speeds up as Roche acquires 89bio for up to $3.5B
The dash for MASH is gaining momentum, with Roche AG acquiring 89bio Inc. and its phase III FGF21…
Roche poised to buy MASH drug developer 89bio for $3.5bn
Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and…